1470nm二极管激光前列腺剜除术在持续口服抗凝或抗血小板药物BPH患者中的疗效与安全性
单中心回顾性分析144例接受1470nm DiLEP的BPH患者,其中49例持续口服抗凝/抗血小板药(A组),95例未用(B组)。两组术后IPSS、QoL、Qmax、PVR均较基线显著改善且组间随访无差异;A组失血量更多、膀胱冲洗时间更长,但输血率和并发症率相似。结论认为持续抗凝/抗血小板不是DiLEP的禁忌。
要点
- 持续口服抗凝/抗血小板患者行1470nm DiLEP,随访12个月功能改善与未用药者相当。
- A组失血量(14.9±7.3 g/L vs 10.2±7.0 g/L)和膀胱冲洗时间(21.1±10.9 h vs 16.1±9.0 h)显著高于B组。
- 两组输血率和并发症率无显著差异,A组仅1例因术前中度贫血需输血。
核心结论
- 1470nm DiLEP对持续口服抗凝或抗血小板药物的BPH患者有效且安全,抗凝治疗未显著影响疗效和并发症率。
研究设计与样本
- 2016年1月至2017年6月单中心144例BPH患者行1470nm DiLEP,A组49例(34.0%)持续口服抗凝/抗血小板药,B组95例(66.0%)未用。
- 术前及术后3、6、12个月评估基线特征、手术数据、围手术期并发症和术后结局。
主要发现
- 两组输血率和并发症率相似,A组1例因术前中度贫血需输血。
临床怎么用
- 对持续口服抗凝或抗血小板药物的BPH患者,1470nm DiLEP可作为有效安全的选项,但需预期失血量更多和膀胱冲洗时间更长。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy and safety of 1470-nm Diode Laser Enucleation of the Prostate (DiLEP) in patients with benign prostatic hyperplasia continuously receiving oral anticoagulants or antiplatelet drugs. METHODS: From January 2016 to June 2017, 144 patients were submitted to 1470-nm DiLEP, including 49 (34.0%) continuously administered anticoagulants or antiplatelet drugs per os due to cardiac and/or cerebrovascular diseases (group A), while 95 (66.0%) were not (group B). Evaluation was performed preoperatively, and at postoperative 3, 6, and 12 months, respectively. Patient baseline features, operative data, perioperative complications, and postsurgical outcomes were assessed. RESULTS: Both groups had comparable preoperative parameters, except age (77.3 ± 7.5 vs 73.2 ± 8.8 years, P = .007). Meanwhile, surgical time, sodium decrease, catheterization duration, and hospital stay markedly differed between the 2 groups. In comparison with group B, group A patients had statistically higher blood loss (14.9 ± 7.3 g/L vs 10.2 ± 7.0 g/L, P < .001) and increased bladder irrigation time (21.1 ± 10.9 hours vs 16.1 ± 9.0 hours, P = .004). One case required blood transfusion in group A, because of moderate anemia preoperatively. Both groups showed similar blood transfusion and complication rates. International Prostate Symptom Score, quality of life score, maximum flow rate, and postvoid residual were markedly improved in both groups at 3-, 6-, and 12-month follow-up postoperatively compared with baseline values. However, no statistically significant differences were observed between the 2 groups in various assessment parameters at follow-up (P > .05). CONCLUSION: These findings demonstrated that 1470-nm DiLEP is efficient and safe in benign prostatic hyperplasia cases receiving continuous oral anticoagulant or antiplatelet drugs. Anticoagulation therapy did not significantly influence the results and complication rates.
引用
- Zhang J, Li J, Wang X, et al. Efficacy and Safety of 1470-nm Diode Laser Enucleation of the Prostate in Individuals With Benign Prostatic Hyperplasia Continuously Administered Oral Anticoagulants or Antiplatelet Drugs. Urology. 2020. PMID: 31972178. doi:10.1016/j.urology.2020.01.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。